Clinical trial · no report yet · Phase 1/Phase 2
KRAS G12C
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT04956640 ↗
- Active, not recruiting
- Eli Lilly and Company
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms
- Interventions
- LY3537982; Pembrolizumab; Cetuximab; Pemetrexed; Cisplatin; Carboplatin
- Arms
- LY3537982 (Dose Escalation) · Experimental
- LY3537982 (Dose Expansion) · Experimental
- LY3537982 (Dose Optimization) · Experimental
- Enrollment
- 540 (estimated)
- Primary outcomes
- Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy
- Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents
- Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumab
- To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximab
- To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation
- Sponsor
- Eli Lilly and Company with Merck Sharp & Dohme LLC
- Start
- Jul 19, 2021
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04956640 · updated May 29, 2026